AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. More Details
Excellent balance sheet and fair value.
Share Price & News
How has AC Immune's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ACIU is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ACIU's weekly volatility (9%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ACIU underperformed the US Biotechs industry which returned 24.4% over the past year.
Return vs Market: ACIU underperformed the US Market which returned 50.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is AC Immune's share price compared to the market and industry in the last 5 years?
Simply Wall St News
11 hours ago | Simply Wall StIs AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
1 month ago | Simply Wall StAC Immune's (NASDAQ:ACIU) Shareholders Are Down 15% On Their Shares
2 months ago | Simply Wall StHow Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Is AC Immune undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ACIU ($6.15) is trading below our estimate of fair value ($21.9)
Significantly Below Fair Value: ACIU is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ACIU is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ACIU is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACIU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACIU is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.5x).
How is AC Immune forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACIU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACIU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACIU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACIU's revenue (10.5% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: ACIU's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACIU is forecast to be unprofitable in 3 years.
How has AC Immune performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACIU is currently unprofitable.
Growing Profit Margin: ACIU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACIU is unprofitable, and losses have increased over the past 5 years at a rate of 21% per year.
Accelerating Growth: Unable to compare ACIU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACIU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).
Return on Equity
High ROE: ACIU has a negative Return on Equity (-34.21%), as it is currently unprofitable.
How is AC Immune's financial position?
Financial Position Analysis
Short Term Liabilities: ACIU's short term assets (CHF220.5M) exceed its short term liabilities (CHF11.1M).
Long Term Liabilities: ACIU's short term assets (CHF220.5M) exceed its long term liabilities (CHF9.4M).
Debt to Equity History and Analysis
Debt Level: ACIU is debt free.
Reducing Debt: ACIU had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACIU has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ACIU has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is AC Immune current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACIU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACIU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACIU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACIU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACIU's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andrea Pfeifer (63 yo)
Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...
CEO Compensation Analysis
Compensation vs Market: Andrea's total compensation ($USD1.93M) is about average for companies of similar size in the US market ($USD1.73M).
Compensation vs Earnings: Andrea's compensation has been consistent with company performance over the past year.
Experienced Management: ACIU's management team is considered experienced (5 years average tenure).
Experienced Board: ACIU's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AC Immune SA's company bio, employee growth, exchange listings and data sources
- Name: AC Immune SA
- Ticker: ACIU
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$446.812m
- Shares outstanding: 72.65m
- Website: https://www.acimmune.com
Number of Employees
- AC Immune SA
- Building B
- EPFL Innovation Park
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with p...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/08 23:58|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.